Literature DB >> 12195648

Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada.

Victoria Kirsh1, Nancy Kreiger.   

Abstract

OBJECTIVE: To examine the association between hormone replacement therapy (HRT) use and breast cancer incidence and to determine whether the association differs according to type of regimen.
METHOD: Data were collected in Ontario from 404 incident cases and 403 age frequency-matched controls, between 1995 and 1996, using a self-administered questionnaire.
RESULTS: Multivariate analyses revealed an elevated odds ratio among long-term (> or = ten years) HRT users (odds ratio (OR) = 1.80, 95% confidence interval (CI) 1.06-3.06). Risk among long-term estrogen-progestin users was substantially higher (OR = 3.48, 95% CI 1.00-12.11) than risk among long-term users of estrogen alone (OR = 1.74, 95% CI 0.93-3.24). Among both estrogen and estrogen-progestin users, positive associations were not observed for durations of use less than ten years.
CONCLUSION: These data suggest that long-term use of HRT increases the risk of breast cancer and that estrogen-progestin therapy may be more detrimental than estrogen use alone.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12195648     DOI: 10.1023/a:1016330024268

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  7 in total

Review 1.  Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis.

Authors:  Nirav R Shah; Jeff Borenstein; Robert W Dubois
Journal:  Menopause       Date:  2005 Nov-Dec       Impact factor: 2.953

2.  Genetic variation in the progesterone receptor and metabolism pathways and hormone therapy in relation to breast cancer risk.

Authors:  Kerryn W Reding; Christopher I Li; Noel S Weiss; Chu Chen; Christopher S Carlson; David Duggan; Kenneth E Thummel; Janet R Daling; Kathleen E Malone
Journal:  Am J Epidemiol       Date:  2009-10-21       Impact factor: 4.897

3.  The induction of KLF5 transcription factor by progesterone contributes to progesterone-induced breast cancer cell proliferation and dedifferentiation.

Authors:  Rong Liu; Zhongmei Zhou; Dong Zhao; Ceshi Chen
Journal:  Mol Endocrinol       Date:  2011-05-12

4.  Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort.

Authors:  Louise A Brinton; Douglas Richesson; Michael F Leitzmann; Gretchen L Gierach; Arthur Schatzkin; Traci Mouw; Albert R Hollenbeck; James V Lacey
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11       Impact factor: 4.254

Review 5.  Progesterone receptors--animal models and cell signalling in breast cancer. Implications for breast cancer of inclusion of progestins in hormone replacement therapies.

Authors:  Catherine Schairer
Journal:  Breast Cancer Res       Date:  2002-10-07       Impact factor: 6.466

6.  An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk.

Authors:  S A Lee; R K Ross; M C Pike
Journal:  Br J Cancer       Date:  2005-06-06       Impact factor: 7.640

7.  Trends in incidence and mortality of female breast cancer during transition in Central China.

Authors:  Yao Cheng; Yaqiong Yan; Jie Gong; Niannian Yang; Shaofa Nie
Journal:  Cancer Manag Res       Date:  2018-11-23       Impact factor: 3.989

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.